Medical cannabis: Tilray strengthens its production capabilities in Europe

Published 2026-10-17

Tilray Medical, a major player in the therapeutic cannabis sector, has just reached an important milestone for its European operations. The company recently obtained a new official license in Portugal, a country that plays a central role in the group's production strategy for the continent.

This specific authorization now allows Tilray to conduct its quality tests directly on-site. Previously, these control steps had to be carried out in external laboratories, which could slow down the distribution process. Thanks to this license, the company gains autonomy and logistical efficiency.

For European patients, this advancement could facilitate access to medical cannabis-based treatments. By improving its control processes, Tilray seeks to meet the strict standards imposed by European health authorities, while increasing its production capacity to meet growing demand.

In France, the debate over the use of medical cannabis remains highly regulated. While the country is currently conducting a national experiment to evaluate the effectiveness of these treatments, companies like Tilray are closely monitoring the evolution of French regulations, which could open up further in the coming years.

This new step in Portugal confirms the desire of major international groups to structure a solid European industry. It now remains to be seen how these increased production capabilities will influence public health policies in the various countries of the European Union.

Sources: Newsweed

More France news

All France news · News by country